b-Arrestins 1 and 2 are multifunctional adaptor proteins originally discovered for their role in desensitizing seventransmembrane receptor signaling via the heterotrimeric guanine nucleotide-binding proteins. Recently identified roles of b-arrestins include regulation of cancer cell chemotaxis and proliferation. Herein, we report that b-arrestin1 expression regulates breast tumor colonization in nude mice and cancer cell viability during hypoxia. b-Arrestin1 robustly interacts with nuclear hypoxiainduced factor-1a (HIF-1a) that is stabilized during hypoxia and potentiates HIF-1-dependent transcription of the angiogenic factor vascular endothelial growth factor-A (VEGF-A). Increased expression of b-arrestin1 in human breast cancer (infiltrating ductal carcinoma or IDC and metastatic IDC) correlates with increased levels of VEGF-A. While the anti-angiogenic drug thalidomide inhibits HIF-1-dependent VEGF transcription in breast carcinoma cells, it does not prevent HIF-1a stabilization, but leads to aberrant localization of HIF-1a to the perinuclear compartments and surprisingly stimulates nuclear export of b-arrestin1. Additionally, imatinib mesylate that inhibits release of VEGF induces nuclear export of b-arrestin1-HIF-1a complexes. Our findings suggest that b-arrestin1 regulates nuclear signaling during hypoxia to promote survival of breast cancer cells via VEGF signaling and that drugs that induce its translocation from the nucleus to the cytoplasm could be useful in anti-angiogenic and breast cancer therapies.
Introduction
b-Arrestin1 (a.k.a. arrestin2) and b-arrestin2 (a.k.a. arrestin3) are ubiquitously expressed multifunctional signaling adaptor proteins originally discovered for their role in desensitizing seven-transmembrane G proteincoupled receptors (GPCRs or 7TMRs) (Lefkowitz and Shenoy, 2005) . b-Arrestins regulate both GPCR and non-GPCR pathways, under normal as well as pathological conditions, including cancer (Lefkowitz et al., 2006) . The two b-arrestin isoforms share roughly 70% sequence identity and in general perform similar functions in GPCR regulation (for example receptor desensitization) (Lefkowitz and Shenoy, 2005) . Studies utilizing small-interfering RNA (siRNA)-mediated depletion and individual isoform repletion of b-arrestin1/2 null mouse embryonic fibroblasts have revealed differential roles in the extent of their endocytic and signaling functions with respect to some GPCRs, and the two isoforms can sometimes function in a reciprocal manner to regulate GPCR signaling (DeWire et al., 2007) . Of the two b-arrestin isoforms, b-arrestin2 is excluded from the nucleus due to the presence of a nuclear export signal that is absent in b-arrestin1 (Scott et al., 2002; Wang et al., 2003; Kang et al., 2005) .
Previous studies indicate that both b-arrestins have a crucial role in mitogenic signaling and chemotaxis of cancer cells (Ge et al., 2004; Buchanan et al., 2006; Dasgupta et al., 2006; Girnita et al., 2007; Raghuwanshi et al., 2008; Zou et al., 2008; Alvarez et al., 2009; Li et al., 2009; Rosano et al., 2009) . In a human colorectal carcinoma cell line, b-arrestin1-mediated c-Src activation was found to be necessary for the transactivation of the epidermal growth factor receptor and downstream AKT activation as well as for cellular chemotaxis in vitro (Buchanan et al., 2006) . Transgenic overexpression of b-arrestin1 leads to rapid tumor progression and increased angiogenesis in mice (Zou et al., 2008) . b-Arrestin2 facilitates the rapid endocytosis of vascular endothelial cadherin in response to vascular endothelial growth factor (VEGF) stimulation leading to endothelial cell permeability (Gavard and Gutkind, 2006) . b-Arrestin2 also mediates endocytosis and downregulation of transforming growth factor-b type III receptor and low levels of this receptor are correlated with cancer invasiveness (Mythreye and Blobe, 2009) . Recent studies have shown that b-arrestin2 specifically acts as a repressor of androgen receptor activity in prostate cancer cells (Lakshmikanthan et al., 2009 ) and b-arrestin2 knockout mice display enhanced lung tumor metastasis (Raghuwanshi et al., 2008) . Thus, there is increasing evidence that b-arrestin1 is associated with cell invasion and proliferation in multiple types of tumors, while b-arrestin2 is bifunctional and promotes or represses specific cancers. While the overexpression of b-arrestin1 accelerates tumor progression in mice, it is unclear whether endogenous b-arrestin1 expression and/or activity are correlated with malignancy.
Malignant transformation of breast tumors involves upregulation of angiogenic factors resulting from tumor hypoxia. Additionally, localized hypoxia in tumors renders them resistant to radiation and chemotherapy. The hypoxia-induced factor-1 (HIF-1) is recognized as the master transcriptional switch during hypoxia, and activates 4100 genes crucial for the cellular adaptation to low oxygen tension (Semenza, 2007) . The HIF-1 transcription factor is a heterodimer consisting of the oxygen-regulated HIF-1a subunit and oxygen-insensitive HIF-1b subunit (a.k.a. aryl hydrocarbon receptor nuclear translocator) . Under normoxia, HIF-1a is hydroxylated at specific proline residues, which leads to its ubiquitination by the E3 ubiquitin ligase and tumor suppressor pVHL (Maxwell et al., 1999) . Consequently, HIF-1a subunit is continuously degraded by the 26S proteasome. During hypoxia, prolyl hydroxylation does not occur and hence HIF-1a is not ubiquitinated and degraded. Stabilized HIF-1a translocates into the nucleus, heterodimerizes with HIF-1b to form a functional transcription factor and binds to specific promoter regions known as hypoxia-responsive elements (HRE) to induce transcription of many genes, especially those required for angiogenesis (for example, VEGF), cell survival (for example, insulin-like growth factor), glucose metabolism (for example, glucose transporter) and invasion (for example, transforming growth factor-a) (Semenza, 2007) . It is also suggested that optimal HIF-1 activity requires p300 binding (Arany et al., 1996) and might involve other juxtaposed transcriptional elements such as AP-1 (Kvietikova et al., 1995) .
Herein, we report a novel interaction between b-arrestin1 and HIF-1a occurring in breast carcinoma cells and further show that this interaction is crucial for HIF-1-dependent gene transcription. We find a positive correlation between b-arrestin1 and VEGF-A expression levels in metastatic human breast cancer tissues, suggesting that b-arrestin1-dependent signaling during adaptation to hypoxia regulates breast tumor metastasis.
Results

b-arrestin1 is upregulated in invasive breast carcinoma
In the human genome, the b-arrestin1 gene maps to chromosome locus 11q13, which is often amplified in breast cancer (Chuaqui et al., 1997; Letessier et al., 2006) . While b-arrestin1 overexpression promotes tumor growth in mice (Zou et al., 2008) , transcriptome and gene profiling studies do not identify an increase in b-arrestin mRNA in breast cancer Minn et al., 2005; Niida et al., 2009 ). On the other hand, we have found a dramatic increase in b-arrestin1 protein levels in invasive breast carcinoma cells (MDAMB-231) when compared with non-invasive cells (HEK-293) and normal breast epithelial cells (Hs 578Bst, American Type Culture Collection (ATCC), Manassas, VA, USA) . b-Arrestin2 is also expressed in MDAMB-231, but at much lower levels than in both HEK-293 and Hs 578Bst. Additionally, in the above non-invasive cells, b-arrestin2 is the more abundant isoform.
We next analyzed the b-arrestin1 protein levels in normal and cancer tissue cores (MaxArray human breast carcinoma tissue microarray slides) by immunostaining with anti-b-arrestin1 antibody (A1CT). About 70% of the infiltrating ductal carcinoma (IDC) tissue sections analyzed had increased levels of b-arrestin1 and its expression was significantly higher in IDC than in normal breast specimens (Figures 1d and e ). Qualitatively similar immunostaining patterns were obtained with a second b-arrestin1-specific antibody (BD Transduction Laboratories, San Diego, CA, USA), but very weak signals were observed with secondary antibody alone or with the anti-b-arrestin2 A2CT (Supplementary Figure S1 ). Hence, the b-arrestin isoform detected in these tissues is predominantly b-arrestin1.
b-arrestin knockdown retards colonization and growth of breast carcinoma cells in experimental metastasis assays Previous studies have indicated that both b-arrestins 1 and 2 are required for chemotaxis of breast cancer cells (Ge et al., 2004) , thereby suggesting that both isoforms might regulate spread of cancer in vivo. Accordingly, we transfected MDAMB-231 cells stably expressing luciferase (231-luc) with either control siRNA or b-arrestin1/2specific siRNA, injected the cells via tail vein into female nude mice and performed bioluminescence imaging (In Vivo Imaging Systems, IVIS, Caliper Life Sciences, Hopkinton, MA, USA) to track metastatic spread of cancer. After tail-vein injections, we detected and quantified the signals in vivo over a period of 5 weeks using the Living Image acquisition and analysis software (Caliper Life Sciences). Although the uptake of both control and b-arrestin1/2 knockdown cells in the lungs was similar at 24 h, stable lung colonization was observed only in control-treated mice, but not in mice that received b-arrestin-depleted cells (Figures 2a and b ). Aliquots of cells used for the injection were immunoblotted for b-arrestin1/2 levels and analyzed for luciferase expression. As depicted in Figures 2c and d , b-arrestin1/2 knockdown cells had 15-20% more luciferase activity than control cells and b-arrestins 1 and 2 were completely knocked down. Additionally, we tested the effect of b-arrestin1 knockdown on the metastatic spread of murine breast cancer cells (4T1) that cause more aggressive tumor metastasis than MDAMB-231 cells in nude mice models. Tail-vein injection of 4T1 cells depleted of b-arrestin1 expression (B80% knockdown) led to delayed tumor growth and an increase in the survival of nude mice (Figures 2e and f) . These data corroborate previous reports that b-arrestins 1 and 2 are critical for tumor metastasis, and identify that b-arrestins 1 and/or 2 are required for viability of breast cancer cells in vivo. Additionally, the experiments with 4T1 cells convey a critical role for b-arrestin1 in breast cancer progression.
b-arrestin1 promotes HIF-1 signaling SK Shenoy et al b-arrestin1 expression is critical for the viability of breast carcinoma cells under hypoxic stress To discern whether expression of b-arrestins 1 and 2 affects cancer cell viability, we performed CellTiter-Glo (Promega, Madison, WI, USA) luminescent cell viability assay on breast carcinoma cells transfected with siRNA targeting no mRNA (control), b-arrestin1 or 2. This assay is based on the quantification of the cellular adenosine-5 0 -triphosphate present, which indicates the presence of metabolically active cells. Under normoxia, no significant differences were observed between control and b-arrestin knockdown cells, suggesting that the general cell viability is unaffected by the depletion of b-arrestin1 or 2. Interestingly, when we treated the cells for 24 h with 100 mM Cobalt chloride (CoCl 2 ), a well-accepted hypoxia mimetic , or induced hypoxia by growing cells in low (1%) oxygen, cell viability was significantly reduced in b-arrestin1, but not in b-arrestin2depleted cells when compared with cells transfected with control siRNA (Figure 3 ). It is known that cancer cells undergo genetic and adaptive changes that allow their survival in a hypoxic environment. Above findings suggest that b-arrestin1 expression facilitates cell survival during hypoxia by influencing adaptive gene programming via its signaling roles.
b-arrestin1 interacts with the oxygen-regulated transcription factor HIF-1a
Based on the effect of b-arrestin1 knockdown on cell survival during hypoxia ( Figure 3) , and on the knowledge about its nuclear localization and nuclear function in forming a complex with p300 that regulates HIF-1 activity (Arany et al., 1996; Kang et al., 2005) , we hypothesized that b-arrestin1 could be modulating the transcriptional activity of HIF-1a, thus regulating the survival of breast carcinoma cells during hypoxia.
To assess whether the b-arrestin-HIF-1a interaction occurs in cells expressing endogenous amounts of the two proteins, we prepared extracts from MDAMB-231 cells that were treated with vehicle or CoCl 2 and tested the interaction by immunoprecipitation and immunoblotting. b-Arrestin1 was detected in HIF-1a immunoprecipitates (IPs) but not in IPs with control IgG (Figure 4a ). b-Arrestin-HIF-1a binding was also detected in b-arrestin IPs isolated from nuclear extracts of MDAMB-231 cells after CoCl 2 treatment (Figure 4b ). Furthermore, we detected colocalization of b-arrestin1 and HIF-1a in the nuclei of CoCl 2 -treated MDAMB-231 cells upon immunostaining and confocal microscopy ( Figure 4c ). The exclusive cytoplasmic distribution of b-arrestin2 is attributed to the presence of a nuclear export signal that is absent in b-arrestin1 (Scott et al., 2002; Wang et al., 2003) . Introduction of this nuclear export signal in b-arrestin1 (barr1Q394L) changes its subcellular distribution to be totally cytoplasmic (Wang et al., 2003) . When we compared b-arrestin1, b-arrestin1Q394L and b-arrestin2 for their binding with HIF-1a, only the wild-type b-arrestin1 formed a robust complex with HIF-1a (Figures 4d and  e ). These findings establish that both b-arrestin1 and HIF-1a interact in the nuclear compartment of breast cancer cells during hypoxia.
b-arrestin1 regulates the transcriptional activity of HIF-1a
To test if the above b-arrestin1-HIF-1a interaction has functional consequences, we analyzed the effect of b-arrestin1 expression on HIF-1-mediated transcription during hypoxia. One of the most characterized HIFdependent genes is the potent endothelial mitogen, VEGF-A, which regulates endothelial cell proliferation and blood vessel formation in both normal and cancerous tissues (Liu et al., 1995) . The VEGF-A gene contains an HRE in its 5 0 -untranslated region and hypoxia induces a rapid and sustained increase in VEGF-A mRNA levels. To assess if HIF-1-dependent VEGF induction involves b-arrestin, we used a luciferase reporter system in which 5XHRE derived from the 5 0 -untranslated region of the human VEGF gene is ligated upstream of the firefly luciferase gene (Figure 5a ). 5XHRE reporter transfection alone led to some basal promoter activity in MDAMB-231 cells. Nonetheless, treatment of cells with CoCl 2 or reduced oxygen levels (1%) significantly increased the luciferase activity ( Figure 5b ). This hypoxia-induced increase was not observed in cells with b-arrestin1 or b-arrestin1/2 knockdown, whereas b-arrestin2 depletion did not significantly change reporter activity (Figures 5b and  c) . These data suggest that HIF-1-dependent transcriptional activity during hypoxia is regulated specifically by b-arrestin1 expression in MDAMB-231 cells. Additionally, we tested HIF-1a-mediated transcriptional activity (Kohout et al., 2001) . Although we found a 1.8-fold CoCl 2 -induced increase in HIF-1 transcriptional response in these b-arrestin null fibroblasts, restoration of b-arrestin1 expression led to a dramatic increase (6-7-fold) in HIFmediated transcription during hypoxia (Figures 5d and  e ). Thus, b-arrestin1 augments HIF-1-directed transcription and there could be potential b-arrestin1-dependent signals with vital roles during hypoxia.
Increase in VEGF levels in invasive ductal carcinoma correlates with increase in b-arrestin1 levels As we observed an increase in b-arrestin1 expression in IDCs (Figure 1) , and because b-arrestin1 expression correlated with HIF-1 transcriptional activity in MDAMB-231 cells ( Figure 5 ), we wondered if this would be reflected in the levels of either HIF-1a or the downstream target of HIF-1, VEGF-A, in IDCs. We analyzed b-arrestin1 and VEGF protein expression by immunostaining with the antibodies anti-b-arrestin1 (A1CT) and anti-VEGF-A (mouse monoclonal C-1), followed by respective secondary antibodies, one conjugated to Alexa Fluor 488 and the other to Alexa Fluor 594 (see Materials and methods). A representative set of confocal images for normal, IDC and metastatic IDC is shown in Figure 6a . The data acquired for b-arrestin1 and VEGF immunostaining for normal breast (n ¼ 10 tissue samples, 22 images), IDC (n ¼ 79 tissue samples, 112 images) and metastatic carcinoma in lymph node (n ¼ 7 tissue samples, 12 images) is summarized as bar graphs in Figure 6b . Although VEGF expression varied from undetectable to very high levels among the different cancer samples, overall both b-arrestin1 and b-arrestin1 promotes HIF-1 signaling SK Shenoy et al VEGF levels were significantly higher (Po0.01) in IDC samples than in normal breast tissues. Despite various immunostaining attempts with available HIF-1a antibodies, we were unable to detect a specific signal for this protein in these breast tissue arrays. Additionally, although there was no direct relationship between the increase in b-arrestin1 and the presence of estrogen receptor, progesterone receptor or expression of p53 in these IDC samples ( Supplementary Table 1 ), we found a positive correlation between b-arrestin1 expression and VEGF-A (Figure 6c ). These findings suggest that an increase in b-arrestin expression could enhance HIF-1dependent transcription of VEGF-A in neoplastic and metastatic breast cancer.
Inhibition of VEGF secretion by anti-angiogenic compounds results from a disruption of b-arrestin1-HIF-1 signaling
The immunomodulatory drug thalidomide was previously shown to suppress angiogenesis, although the mechanism was not unknown (D'Amato et al., 1994; Figg, 2006; Holaday and Berkowitz, 2009 ). It was further suggested that thalidomide inhibits secretion of VEGF from tumors and bone marrow stromal cells leading to decreased endothelial cell migration and adhesion (Dredge et al., 2002; Vacca et al., 2005) . When we treated MDAMB-231 cells with thalidomide, we saw a complete inhibition of HIF-1-dependent transcription as measured by 5XHRE-luciferase reporter activity (Figure 7a ). Paradoxically, HIF-1a stabilization during hypoxia was not affected and similar amounts of HIF-1a were detected in cell extracts with or without thalidomide treatment (Figure 7b ). However, when we analyzed b-arrestin1 distribution in thalidomide-treated cells, we observed a predominant cytoplasmic translocation of endogenous b-arrestin1 from the nucleus and only 10-15% protein remained in the nucleus as assessed by immunostaining ( Figure 7c ). Furthermore, while hypoxia induced a robust HIF-1a and b-arrestin1 colocalization in the nuclear compartment, addition of thalidomide under hypoxia resulted in relocation of b-arrestin1-HIF-1 complexes to the perinuclear compartments ( Figure 7d ). Additionally, the tyrosine kinase inhibitor, imatinib mesylate, which has been shown to exhibit anti-angiogenic effects (Vlahovic et al., 2006) caused a similar mislocalization of b-arrestin1-HIF-1a into perinuclear compartments (Figure 7d ). However, unlike thalidomide, treatment of MDAMB-231 cells with imatinib inhibited the accumulation of HIF-1a during hypoxia (Figure 7e ). These data strongly suggest that b-arrestin1-HIF-1 interaction in the nucleus is required for inducing VEGF transcription and secretion in carcinoma cells. Moreover, drugs that can cause nuclear export of b-arrestin1 could prove useful in reducing gene transcription during hypoxia and serve as inhibitors of breast cancer angiogenesis.
Discussion
Recent studies have indicated that in addition to the neoplastic role played by GPCRs and G proteins in a variety of cancers (Daaka, 2004) , b-arrestins may also have a crucial role in the progression of colorectal, ovarian and lung cancer in mice (Buchanan et al., 2006; Raghuwanshi et al., 2008; Rosano et al., 2009 ). We have b-arrestin1 promotes HIF-1 signaling SK Shenoy et al found that b-arrestin1 regulates breast cancer cell survival during hypoxia through a novel interaction with the transcription factor, HIF-1. Additionally, our analyses of human breast tumors indicate that an upregulation of b-arrestin1 correlates with an increase in VEGF-A, a key regulator of tumor angiogenesis. Our data also establishes that nuclear export of b-arrestin1 disrupts HIF-1-dependent transcription of VEGF-A, and that formation and localization of b-arrestin-HIF-1a complexes could be fundamental for cell survival during hypoxia. Thus far, few studies have addressed the mechanistic role of b-arrestins in promoting nuclear transcription (Kang et al., 2005) . However, its role in inhibiting nuclear transcription has dominated among the spectrum of its recently discovered functions (DeWire et al., 2007) . The finding that b-arrestin1 binds and potentiates HIF-1 activity provides an exciting and unexpected view of how signal transduction during hypoxia might be regulated. We propose that b-arrestin1 acts as a scaffolding protein for recruiting and stabilizing HIF-1 and thus regulating gene transcription during hypoxia. Whether this involves binding of b-arrestin1 with other co-factors to promote HIF-1a and HIF-1b dimerization or whether b-arrestin1 prevents binding of repressor elements that inhibit HIF-1 activity remains to be determined. Nonetheless, our findings demonstrate a novel role of b-arrestin1 in promoting expression of the HIF-1 transcriptional target VEGF-A.
VEGF-A belongs to a family of cytokines that bind to and activate VEGF receptors to stimulate proliferation, migration and recruitment of endothelial cells (Leung et al., 1989; Ferrara et al., 2003) . VEGF-A-VEGF receptor 2 interaction has a crucial role in both b-arrestin1 promotes HIF-1 signaling SK Shenoy et al developmental and pathological angiogenesis, and there is increased expression of these molecules in many solid tumors. The importance of targeting tumor angiogenesis was suggested in early 1970s (Folkman et al., 1971) and has since led to cancer drugs targeting this pathway, such as Bevacizumab (a humanized monoclonal antibody that binds VEGF-A), VEGF-Trap (soluble fusion proteins of extra-cellular domains of VEGF receptors 1 and 2 and the Fc portion of human IgG), Sunitinib (VEGF receptor and RTK inhibitor) (Holaday and Berkowitz, 2009 ). These molecules bind either the VEGF ligand or its receptor and thus prevent signal transduction that is required for endothelial cell proliferation and subsequent angiogenesis. Previous studies have also shown that thalidomide (that has reemerged as a drug for multiple myeloma) and imatinib (that inhibits c-Abl and other tyrosine kinases) reduce the accumulation of VEGF as well as inhibit tumor angiogenesis and growth, although the exact mechanism was not known (D'Amato et al., 1994; Ebos et al., 2002; Beppu et al., 2004; Figg, 2006; Vlahovic et al., 2006; Holaday and Berkowitz, 2009) , Our studies reveal that these latter two compounds prevent b-arrestin1-HIF-1a interaction in the nuclear compartment during hypoxia and inhibit VEGF transcription. In summary, our findings strongly suggest that b-arrestin1 has a proangiogenic role in breast carcinoma, and predictably, drugs that inhibit its nuclear activity or stimulate nuclear export could be useful in inhibiting breast cancer angiogenesis and metastasis.
Materials and methods
Reagents
Cell lines. MDAMB-231 cells were obtained from ATCC and maintained in Leibowitz's L15 medium, supplemented with 14 mM NaHCO 3 and 10% fetal bovine serum and grown at 37 1C, 5% CO 2 . MDAMB-231 and 4T1 cells stably transfected with luciferase were generously provided by Dr P Casey (Kelly et al., 2006) . HEK-293 cells from ATCC were cultured in minimal essential medium supplemented with 10% fetal bovine serum. Normal breast epithelial cells (Hs 578Bst, ATCC) were grown in ATCC Hybri-Care Medium supplemented with 1.5 g/l sodium bicarbonate, 30 ng/ml mouse epidermal growth factor and 10% fetal bovine serum.
Plasmids. Flag-b-arrestin1, Flag-b-arrestin2 and 5XHREluciferase plasmids have been previously described (Moeller et al., 2004; Shenoy et al., 2008) . Q394L mutation in Flag-b-arrestin1 was introduced by site-directed mutagenesis.
Antibodies. Anti-b-arrestins 1 2 antibodies have been previously described (Attramadal et al., 1992) and were a generous gift from Dr RJ Lefkowitz. Other anti-b-arrestin antibodies include monoclonal anti-b-arrestin1 (BD Transduction Laboratories) and K-16 goat polyclonal antibody (Santa Cruz Biotechnology Inc). Rabbit polyclonal anti-HIF-1a (Novus Biologicals, Littleton, CO, USA) was used for immunoblotting, and mouse monoclonal anti-HIF-1a (Santa Cruz Biotechnology Inc) was used for immunostaining and immunoprecipitation. Anti-VEGF-A antibody (mouse monoclonal C-1, Santa Cruz Biotechnology Inc) was used in immunostaining procedures. To label b-arrestin1, anti-b-arrestin1 antibody (A1CT) was used at 1:300 dilution in 2% bovine serum albumin followed by Alexa Fluor 488 goat anti-rabbit IgG (H þ L). HIF-1a was detected with a mouse monoclonal anti-HIF-1a antibody (1:300 dilution) followed by Alexa Fluor 594 goat anti-mouse IgG (H þ L). Confocal images were obtained on a Zeiss LSM510 laser-scanning microscope (Carl Zeiss Inc, Thornwood, NY, USA) using multitrack sequential excitation (488 and 568 nm) and emission (515-540 nm, green fluorescent protein; 585-615 nm, Texas Red) filter sets using either 100 Â or 40 Â oil immersion objectives. Breast tissue sections on Zymed MaxArray Human Breast Carcinoma (60 cancer cores plus 1 normal tissue) and IMGENEX HISTO-Array tissue microarray slides (50 cancer cores plus 10 normal) were deparaffinized and rehydrated. After this the sections were incubated in a blocking buffer (3% bovine serum albumin) in a humidified chamber. b-arrestin1 and HIF-1a were immunostained as above. To detect b-arrestin2, anti-b-arrestin2 antibody A2CT (1:250 dilution) was used. VEGF-A was detected with a mouse monoclonal antibody followed by Alexa Fluor 594 goat anti-mouse IgG (H þ L) and nuclei were labeled with DRAQ5 (Axxora LLC, San Diego, CA, USA). Confocal images were acquired in a random order for different samples in a tissue microarray by high-resolution confocal microscopy (Zeiss LSM 510, and Â 40 or Â 100 oil immersion objective). Sections that were stained only with secondary antibodies served as negative controls. Pixel intensities for different fluorophore signals in each image were determined with the MetaMorph software.
Luciferase reporter assay MDAMB-231 cells were transfected with luciferase reporter plasmid alone or with different siRNA oligonucleotides (control, barr1, barr2 or barr1/2) using Lipofectamine 2000; 48 h later, transfected cells were plated on 24-well dishes. Next day cells were serum starved for 1-2 h and incubated at 1% O 2 or treated with 100 mM CoCl 2 for 5 h. After this, cells were lysed, collected and assayed using a Luciferase Reporter Assay kit (Promega) according to the included protocol.
Viability assays MDAMB-231 cells were transfected with control, barr1 or barr2 siRNA and 48 h after transfection, they were split into 24-well dishes. Cells were incubated at 1% O 2 or treated with 100 mM CoCl 2 , after which the adenosine-5 0 -triphosphate content was measured with CellTiter-Glo luminescent cell viability assay kit (Promega) according to the included protocol.
In vivo measurements Adult female nude mice used in the animal studies were purchased from Charles River. All animal experiments complied with Duke University Institutional Animal Care and Use Committee guidelines. A total of 1 Â 10 6 MDAMB-231-luciferase cells or 50 000 4T1-luciferase cells were used per tail-vein injection. A highly sensitive cooled charge-coupled device camera mounted in a light-tight box (IVIS) was used to perform bioluminescent imaging on animals that were anesthetized with 1-3% isoflurane. The acquisition and analysis software Living Image controlled imaging and quantification of signals. Prior to imaging, each animal was injected with D-luciferin at 100 mg/kg i.p. Light emitted from the bioluminescent tumors cells was detected by the IVIS camera system, integrated, digitized and displayed. Regions of interest from displayed images were marked surrounding regions with luminescence and quantified as total photons/s using Living Image (Caliper Life Sciences). Since the imaging was non-invasive, the same animals were analyzed for tumor growth up to 30-35 days after which animals had to be euthanized for humane reasons.
